Fig. 1From: Screening for immune-potentiating antigens from hepatocellular carcinoma patients after radiofrequency ablation by serum proteomic analysisRepresentative 2-DE serum protein profiles before and after RFA treatment for hepatocellular carcinoma patients. These differentially expressed protein spots (labelled as A1 to A18 and B2 to B14) were subsequently identified by MALDI-TOF MS/MS analysesBack to article page